Market icon
Финансы·Акции

Побьет ли Johnson & Johnson (JNJ) квартальную прибыль?

Market icon
Финансы·Акции

Побьет ли Johnson & Johnson (JNJ) квартальную прибыль?

Да

87% вероятность
Polymarket
НОВОЕ

Да

87% вероятность
Polymarket
НОВОЕ
As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS. Trader consensus on Polymarket prices an 87% implied probability that Johnson & Johnson (JNJ) will beat Q1 2026 non-GAAP EPS consensus estimates around $2.68 per share, driven by the company's track record of surpassing expectations—beating EPS by an average 2.2% over the last four quarters—and robust Q4 2025 results reported January 21, with revenue of $24.6 billion topping forecasts amid 7.1% operational sales growth. Elevated 2026 guidance for adjusted earnings of $11.43–$11.63 per share and sales near $100.5 billion, exceeding analyst projections, bolsters sentiment alongside a "Buy" rating from 19 analysts and average price targets of $243. Key catalyst: Q1 earnings release April 14.

As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.

If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)

If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”

Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Объем
$311
Дата окончания
14 апр. 2026 г.
Открытие рынка
Mar 30, 2026, 7:54 PM ET

Источник определения исхода

https://seekingalpha.com/

Resolver

0x65070BE91...
As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS. Trader consensus on Polymarket prices an 87% implied probability that Johnson & Johnson (JNJ) will beat Q1 2026 non-GAAP EPS consensus estimates around $2.68 per share, driven by the company's track record of surpassing expectations—beating EPS by an average 2.2% over the last four quarters—and robust Q4 2025 results reported January 21, with revenue of $24.6 billion topping forecasts amid 7.1% operational sales growth. Elevated 2026 guidance for adjusted earnings of $11.43–$11.63 per share and sales near $100.5 billion, exceeding analyst projections, bolsters sentiment alongside a "Buy" rating from 19 analysts and average price targets of $243. Key catalyst: Q1 earnings release April 14.

As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.

If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)

If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”

Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Объем
$311
Дата окончания
14 апр. 2026 г.
Открытие рынка
Mar 30, 2026, 7:54 PM ET

Источник определения исхода

https://seekingalpha.com/

Resolver

0x65070BE91...
As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.

Не доверяй внешним ссылкам.

Часто задаваемые вопросы

«Побьет ли Johnson & Johnson (JNJ) квартальную прибыль?» — это рынок прогнозов на Polymarket с 2 возможными исходами, где трейдеры покупают и продают акции на основе своих прогнозов. Текущий лидирующий исход — «Побьёт ли Johnson & Johnson (JNJ) квартальные ожидания по прибыли?» с 87%. Цены отражают вероятности сообщества в реальном времени. Например, акция по цене 87¢ означает, что рынок коллективно оценивает вероятность этого исхода в 87%. Эти коэффициенты постоянно меняются. Акции правильного исхода можно обменять на $1 каждую при разрешении рынка.

«Побьет ли Johnson & Johnson (JNJ) квартальную прибыль?» — недавно созданный рынок на Polymarket, запущен Mar 30, 2026. Как ранний рынок, это твоя возможность быть среди первых трейдеров, устанавливающих коэффициенты и формирующих начальные ценовые сигналы. Ты также можешь добавить эту страницу в закладки, чтобы следить за объёмом и активностью торгов.

Чтобы торговать на «Побьет ли Johnson & Johnson (JNJ) квартальную прибыль?», просмотри 2 доступных исходов на этой странице. Каждый исход показывает текущую цену, представляющую подразумеваемую вероятность рынка. Чтобы занять позицию, выбери исход, который считаешь наиболее вероятным, выбери «Да» для торговли в его пользу или «Нет» для торговли против, введи сумму и нажми «Торговать». Если твой выбранный исход окажется верным, твои акции «Да» принесут $1 каждая. Если нет — $0. Ты также можешь продать акции до разрешения.

Текущий фаворит для «Побьет ли Johnson & Johnson (JNJ) квартальную прибыль?» — «Побьёт ли Johnson & Johnson (JNJ) квартальные ожидания по прибыли?» с 87%, что означает, что рынок оценивает вероятность этого исхода в 87%. Эти коэффициенты обновляются в реальном времени по мере покупки и продажи акций. Заходи чаще или добавь страницу в закладки.

Правила разрешения «Побьет ли Johnson & Johnson (JNJ) квартальную прибыль?» точно определяют, что должно произойти, чтобы каждый исход был объявлен победителем, включая официальные источники данных, используемые для определения результата. Ты можешь просмотреть полные критерии разрешения в разделе «Правила» на этой странице над комментариями. Мы рекомендуем внимательно прочитать правила перед торговлей, так как они определяют точные условия, особые случаи и источники.